Decreased SIRT1 and LSECs dysfunction could be potential therapeutic targets for mitigating the MASLD progression, but the underlying mechanism regarding the decreased SIRT1 in senescent and aged LSECs deserve further exploration. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.